LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $98.14 Consensus PT from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $98.14.

Several equities analysts have weighed in on LMAT shares. Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $90.24 on Friday. LeMaitre Vascular has a one year low of $65.16 and a one year high of $109.58. The company has a market cap of $2.04 billion, a PE ratio of 49.31, a PEG ratio of 2.22 and a beta of 0.89. The firm has a 50-day moving average of $86.09 and a 200-day moving average of $93.42.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. During the same period in the prior year, the firm posted $0.44 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, equities research analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 0.89%. LeMaitre Vascular’s payout ratio is presently 41.24%.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new stake in LeMaitre Vascular during the 4th quarter worth about $14,900,000. Rockefeller Capital Management L.P. bought a new stake in shares of LeMaitre Vascular during the fourth quarter valued at about $7,787,000. Segall Bryant & Hamill LLC purchased a new stake in shares of LeMaitre Vascular in the fourth quarter worth about $5,446,000. Invesco Ltd. boosted its position in shares of LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after acquiring an additional 58,720 shares during the period. Finally, GAMMA Investing LLC grew its stake in LeMaitre Vascular by 7,486.5% during the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier’s stock valued at $4,519,000 after acquiring an additional 53,154 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.